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Abstract 
Background: Despite large interpatient variability in dose response, heparin is utilized for 
treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in 
obese patients are conflicting. Objective: The objective was to evaluate the time and dose 
required to achieve a therapeutic activated partial thromboplastin time (aPTT) in nonobese, 
obese, and severely obese patients using a pharmacist-directed heparin dosing protocol. 
Methods: This was a retrospective cohort study in a single center community hospital inpatient 
setting. Adult patients receiving heparin for VTE treatment from July 1, 2013, to July 31, 2015, 
were evaluated. Patients were categorized into 3 groups: nonobese (BMI < 30 kg/m2), obese 
(BMI = 30-39.9 kg/m2), and severely obese (BMI ≥ 40 kg/m2). Data on height, weight, initial 
bolus dose, initial infusion rate, time to therapeutic aPTT, and therapeutic infusion rate were 
collected. Dosing body weight (DBW) was utilized for patients 20% over their ideal body weight 
(IBW). The primary outcome was time to therapeutic aPTT. Results: Analysis included 298 
patients. Median times to therapeutic aPTT (hours:minutes) in the nonobese, obese, and severely 
obese were 15:00 (interquartile range [IQR] = 8:05-23:21), 15:40 (IQR = 9:22-25:10), and 15:22 
(IQR = 7.54- 23:40), respectively (P = 0.506). There was no difference in bleeding among the 
nonobese (14%), obese (13.9%), or severely obese groups (7.9%; P = 0.453). No adverse 
thrombotic events occurred during hospitalization. Conclusion: Using a DBW for heparin 
dosing in patients 20% over their IBW resulted in similar times to therapeutic aPTT and adverse 
events in the nonobese, obese, and severely obese. 
 
Background 
 
Venous thromboembolism (VTE), including deep-vein thrombosis (DVT) and pulmonary 
embolism (PE), occurs in 104 out of every 100 000 individuals with up to 4.8% and 7.7% 
developing recurrence or adverse bleeding events within 30 days.1 The obese population is 
more likely to develop a VTE compared with the nonobese population.2-4 The prevalence of 
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obesity (body mass index [BMI] ≥ 30 kg/m2) in the United States continues to rise, with 
regional obesity ranging from 25.2% to 31.2% and the Midwest region having the second 
highest prevalence at 30.7%.5 Intravenous heparin is frequently a drug of choice in hospitalized 
patients with VTE, but weight-based dosing is challenging in obese and severely obese patients 
because of the drug’s unpredictable pharmacokinetic properties. 
Heparin’s distribution is limited primarily to blood volume. 6,7 Because of limited distribution 
into adipose tissue, dosing lower than institutional protocol has been observed in obese patients 
to avoid potential overdosing and subsequent adverse bleeding events.8 Subjects included in 
early trials establishing weight-based heparin dosing for acute VTE had a mean weight of 80 
kg, and these studies did not address dosing in the obese patient population.9,10 More than 2 
decades since those studies, the average weight of patients has increased, leaving the question 
of what weight is the most appropriate to use when dosing heparin for VTE treatment.11 
Implementation of pharmacist-directed heparin therapy using standardized dosing protocols has 
been reported.12,13 Pharmacist-directed heparin adjustments lead to an increased number of 
patients within therapeutic range compared with physician adjustments.12 A pharmacist-directed 
heparin dosing protocol was implemented in our hospital in 2008 (Table 1). The protocol 
utilizes actual body weight (ABW) unless the patient is 20% over their ideal body weight 
(IBW), at which point a dosing body weight (DBW) is used. Ideal and DBW calculations are 
displayed in Table 2. Regardless of weight, the initial bolus dose and initial infusion rate are 
limited to 10 000 U and 2500 U/h, respectively. Serial activated partial thromboplastin time 
(aPTT) values are used to guide dosing, and dose titrations are made to achieve a therapeutic 
aPTT of 57 to 96 s, determined based on laboratory correlation to 0.3 to 0.7 U/mL by an anti-
Xa activity assay. Multiple studies have demonstrated a lower risk of recurrent VTE when 
therapeutic aPTTs are achieved rapidly.14,15 With obesity steadily rising in the United States, it 
is important to assess optimal drug dosing in this patient population. The objective of this study 
was to evaluate time to first therapeutic aPTT and doses required to achieve a therapeutic aPTT 
in nonobese, obese, and severely obese patients within our institution when a pharmacist-
directed heparin dosing protocol was utilized. 
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Materials and Methods 
Study Design and Population 
This was a retrospective, single-center cohort study. RxConsult, a proprietary heparin dosing and 
monitoring program within the institution, was utilized to identify patients 18 years or older who 
were receiving heparin for the indication of VTE treatment, including DVT or PE, and managed 
by the pharmacy dosing protocol from July 1, 2013, to July 31, 2015. Indication for heparin 
therapy was based on prescriber documentation in the consult to pharmacy for heparin dosing; 
therefore, if patients had both DVT and PE, it was not captured for the purposes of this 
evaluation. RxConsult is a computer program designed for our institution to assist with dosing 
and monitoring of patients receiving therapeutic heparin. When a new patient is initiated on 
heparin, a new patient-specific profile must be entered into RxConsult, including the patients’ 
name, age, sex, height, weight, and indication. RxConsult will calculate the patient’s IBW and 
determine if the patient’s ABW is 20% over IBW to determine the correct bolus dose and 
infusion rate for the patient based on our dosing protocol. Each aPTT is entered into RxConsult, 
and the resultant rate change and/or bolus will be calculated by the program. Patients were 
excluded if they had a therapeutic aPTT obtained prior to steady state, which was defined as 6 
hours from heparin initiation. RxConsult was used to extract base- line demographics and dosing 
information, including age, sex, height, ABW, indication, aPTT values, time to first therapeutic 
aPTT, and heparin information, which included initial bolus dose, initial infusion rate, 
therapeutic infusion rate, and duration of heparin therapy. Bleeding events and recurrent 
thrombotic events were identified from the physician discharge summary, and use of 
thrombolytic agents was identified via the electronic medical record. Thrombolytic agents 
included systemic alteplase 50 or 100 mg and catheter-directed tenecteplase 2.5, 5, or 10 mg. 
 
Outcomes 
 
The primary outcome was time to first therapeutic aPTT. A therapeutic aPTT was considered 57 
to 96 s per institutional standards. Time to therapeutic aPTT was calculated in hours from the 
start of bolus dose to the first laboratory-reported therapeutic aPTT. Secondary outcomes 
included bleeding or thrombotic events while receiving heparin therapy and percentage of 
therapeutic aPTT values. Bleeding was defined as either a drop in hemoglobin from a baseline of 
≥2 g/dL with subsequent transfusion of 2 or more units of packed red blood cells (PRBCs) while 
on heparin therapy or documented bleeding by the provider in the discharge summary. 
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Thrombotic events were defined as documentation of a thrombus in a new location and/or 
extension of current thrombus after initiation of heparin. 
 
Data Analysis 
 
Patients were categorized into 3 groups based on BMI: nonobese (BMI < 30 kg/m2), obese (BMI 
= 30-39.9 kg/m2), and severely obese (BMI ≥ 40 kg/m2).16 Continuous data were described 
using means and SDs for variables considered to be normally distributed and medians and 
interquartile ranges (IQRs) for variables considered to be nonnormally distributed. Baseline 
demographics and clinical characteristics were compared between groups using analysis of 
variance, with Dunnett t-test for post hoc comparisons when needed. χ2 Analyses and Kruskal-
Wallis tests were used for nonparametric data. Patients with 3 or more consecutive therapeutic 
aPTTs, representing a minimum of 18 hours of a consistent infusion rate, were further analyzed 
to determine dose based on ABW, IBW, and DBW. Statistical analysis was conducted using 
Statistical Package for Social Sciences version 23.0 (SPSS v23.0). The study was approved by 
the institutional review board of the hospital. 
 
Results 
 
A total of 298 patients were eligible for study inclusion. Four patients were excluded for 
therapeutic aPTTs obtained prior to steady state, leaving a total of 294 patients for final 
analysis. Patient characteristics are dis- played in Table 3. Patients in the severely obese 
group (mean ± SD = 57.3 ± 15.6 years) were younger than those in the nonobese (66.2 ± 16.5 
years, P < 0.001) and obese groups (65.8 ± 14.5, P = 0.001). 
 
 
 
Median time to therapeutic aPTT (hours:minutes) was 15:00 (IQR = 8:05-23:21) for the 
nonobese group, 15:40 (IQR = 9:22-25:10) for the obese group, and 15:22 (IQR = 7:54-23:40) 
for the severely obese group (P = 0.506). Subgroup analysis was completed for 140 patients who 
had at least 3 consecutive therapeutic aPTT values (60 non- obese, 52 obese, and 28 severely 
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obese). The mean ± SD infusion rate for nonobese patients was 17.2 ± 5 U/kg/h based on 
ABW and 18.4 ± 5.6 U/kg/h based on DBW. Obese patients required a mean ± SD of 15.9 ± 4.4 
U/kg/h based on ABW and 20.2 ± 5.7 U/kg/h based on DBW. Severely obese patients required 
a mean ± SD of 13.9 ± 3.9 U/kg/h based on ABW and 20.8 ± 6 U/kg/h based on DBW. A total 
of 29 patients (55.8%) and 13 patients (46.4%) in the obese and severely obese groups, compared 
with 21 (35%) in the nonobese group, required an infusion rate above the initial dose of 18 
U/kg/h to achieve consecutive therapeutic aPTT values (P = 0.087). 
 
Table 4 displays efficacy and safety outcomes. Bleeding events occurred in 14%, 13.6%, and 
7.9% of nonobese, obese, and severely obese groups, respectively (P = 0.453). Catheter-directed 
tenecteplase was given in 17 patients (7 nonobese, 6 obese, and 4 severely obese), and 
systemic alteplase was administered in 6 patients (2 nonobese, 1 obese, and 3 severely obese). 
Of the patients who received a thrombolytic prior to heparin, 3 nonobese, 3 obese, and 0 severely 
obese experienced a bleeding event (33.3%, 42.9%, and 0%, respectively). There were no 
thrombotic events documented in any group. 
 
 
 
Discussion 
 
Optimal heparin dosing has been controversial since the early 1990s and with increasing 
weight trends across the United States, the controversy continues. When heparin is used for the 
treatment of VTE, weight-based heparin dosing is recommended because it improves attainment 
of target aPTT values.9 However, in patients categorized as obese or severely obese, there is 
currently no consensus on the most appropriate weight that should be used for dosing.17 The 
nomogram proposed by Raschke et al9 utilizes ABW. However, the study included patients with 
a mean weight of 80.9 kg, with only 9 of 62 (14.5%) patients weighing more than 100 kg.9 
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Studies by Hull et al14 and Hirsh et al15 suggest that VTE recurrence is reduced when the lower 
threshold of therapeutic is exceeded within 24 hours. In obese patients with a BMI >30 kg/m2 
treated with heparin for VTE, 89.3% of patients received a bolus dose less than the 
recommended 80 U/kg and 76.2% had an initial infusion rate below the recommended dose of 18 
U/kg/h. This study describes a prescribing pattern of physicians approximating final therapeutic 
infusion rate based on experience instead of adhering to institutional protocol. They separately 
interviewed 8 physicians who stated that they were aware of weight-based dosing, but the large 
doses required for obese patients was concerning for bleeding events, leading them to decrease 
the dose.8 Additionally, 28.6% and 14.3% of the study patients failed to achieve therapeutic 
aPTTs within 24 and 48 hours, respectively.8 These results highlight the need to reassess and 
clearly define dosing strategies in the increasingly prevalent obese population. 
 
With more than one-third of the US population being obese or severely obese, reevaluating the 
appropriate dosing strategy is important.18 Literature on heparin dosing in the obese population is 
sparse and is further limited by lack of a standardized definition of obesity and calculation for 
DBW. Recent guidance for management of heparin in VTE suggests that a DBW may be an 
appropriate approach for obese patients.17 In our cohort, a pharmacist managed heparin dosing 
protocol using a DBW for patients weighing greater than 20% over their IBW resulted in a 
therapeutic aPTT within approximately 15 hours of infusion initiation for nonobese, obese, and 
severely obese patients. Our protocol requires aPTT values to be ordered every 6 hours until a 
patient achieves 2 consecutive therapeutic aPTT values. We recognized that laboratory blood 
draws are often collected after the ordered time; therefore, a therapeutic aPTT value at 
approximately 15 hours likely represents the second aPTT. 
 
To our knowledge, only 1 other study evaluating the use of a DBW for therapeutic heparin 
infusions exists. Fan et al19 evaluated time to therapeutic aPTT with ABW and DBW in 
preimplementation and postimplementation of an institutional protocol. Their protocol calculated 
a DBW using the same formula as in our study. However, a DBW was used for all patients >30% 
over IBW, whereas ours utilized DBW for patients 20% over their IBW. The mean weight of the 
obese group in the preimplementation phase was 104.7 ± 11.5 kg, and only 31 patients (40.8%) 
achieved a therapeutic aPTT within 24 hours. After implementation of the DBW protocol, 44 
patients (57.1%) achieved a therapeutic aPTT within 24 hours, and the mean weight of the 
postimplementation obese group 138.7 ± 35.6 kg. The infusion rate in the obese group to achieve 
a therapeutic aPTT was found to be 18.2 U/kg/h utilizing DBW, which correlates well with the 
Raschke nomogram.9,10 Similar to our study, there was no difference found in bleeding events 
when using a DBW in obese patients.19 
 
Rapidly exceeding the lower limit of therapeutic aPTT value lowers the risk of recurrent VTE, 
thus, making initial dosing and subsequent titrations crucial.8,13,20 Shin and Harthan21 utilized a 
weight-based dosing heparin protocol specific to medicine, neurology, and cardiac patients to 
evaluate time to exceed the lower limit of therapeutic aPTT. Utilizing ABW, they demonstrated 
mean ± SD time (in hours) to therapeutic aPTT for patients <100 kg, 100 to < 125 kg, 125 to < 
150 kg, and ≥150 kg of 12.9 ± 9.2, 15.5 ± 12.9, 18.1 ± 15.8, and 23.8 ± 27.9, respectively (P = 
0.002), suggesting that body weight affects the time to therapeutic aPTT.21 Because heparin does 
not readily distribute into the less vascular adipose tissue, the dose requirements of heparin in 
obese patients are not directly proportional to their ABW.  
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A subgroup analysis of patients from our cohort with a stable therapeutic infusion demonstrated 
that DBW correlated more closely with our protocol dose of 18 U/kg/h. Obese and severely 
obese patients required doses of 20.2 ± 5.7 and 20.8 ± 6 U/kg/h, respectively, based on DBW. 
The nonobese population also closely aligned with DBW; however, DBW does not differ 
significantly from ABW in nonobese patients. 
 
Our study had a slightly higher rate of bleeding events compared with other published studies. 
This may have been a result of our definition of bleeding, which included a decrease in 
hemoglobin with subsequent transfusion of PRBCs and/or documentation of bleeding in the 
discharge summary. Some other studies only included a hemoglobin decrease with transfusion of 
PRBCs. Similar to other studies evaluating heparin in obese populations, no difference in 
bleeding events was observed between the nonobese, obese, or severely obese groups.19,21 We 
evaluated additional thrombotic events until patient discharge and found no additional 
thrombotic events in any of the patients included, which may be limited by our definition. We 
further analyzed bleeding in patients who received thrombolytic agents prior to heparin 
initiation. No difference in bleeding was found between the nonobese, obese, or severely obese 
patients, with 33.3% (3/9), 42.9% (3/7), and 0% (0/7), respectively, in patients who received a 
thrombolytic.  
 
Our study is limited by the single-center cohort and retrospective design. Much like the current 
literature, our study is also limited by the overall small sample size and the lower number of 
patients in the severely obese weight category. Use of the discharge summary to identify 
documentation of bleeding and/or thrombotic events may have underestimated adverse bleeding 
events and/or secondary thrombotic events. Additionally, our primary outcome of time to 
therapeutic aPTT does not necessarily correlate with achievement of steady state, especially 
because only 47.6% of our patient population had 3 consecutive therapeutic aPTTs, and we did 
not assess time to exceed the lower limit of therapeutic aPTT. We did not include baseline 
characteristics that might put patients at increased risk of VTE, such as active cancer or 
preexisting hypercoagulability states, or increased risk for bleeding, including concomitant use 
of anticoagulants and antiplatelet agents or preexisting renal dysfunction. We also did not 
investigate indications for administration of thrombolytic agents. 
 
Conclusion 
The median time to therapeutic aPTT did not differ in nonobese, obese, or severely obese 
patients when a DBW was utilized in patients weighing 20% over their IBW. Our findings 
support the use of a DBW for patients weighing 20% over their IBW. 
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